|
Positive Data on MediciNova's MN-221 – Analyst Blog
NASDAQ MediciNova is developing MN-221, a highly selective beta(2)-adrenergic receptor agonist, for the treatment of acute exacerbations of asthma and COPD. In 2004, MediciNova licensed exclusive rights to MN-221 from Kissei Pharmaceutical Co., Ltd. in all … Drug trial signals hope for asthma sufferers MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat … Illinois Investor Commits to Buy MediciNova Stock |
View full post on asthma – Google News